扶阳益气方治疗卵巢癌化疗后脾肾阳虚证的临床研究

发布时间：2018-04-18 20:06

  本文选题：扶阳益气方 + 脾肾阳虚　； 参考：《云南中医学院》2017年硕士论文

【摘要】：目的:通过本临床试验,观察与评价扶阳益气方治疗卵巢癌化疗后脾肾阳虚证的临床疗效。探讨卵巢癌化疗后脾肾阳虚证的治疗方法和思路,为卵巢癌患者化疗的顺利进行及完成提供保证,以提高卵巢癌患者生存质量,延长生存期。方法:将符合本研究入组标准的病例,随机分为2组:治疗组30例和对照组30例。治疗组用扶阳益气方+参芪扶正注射液+常规治疗,对照组仅予参芪扶正注射液+常规治疗,两组均治疗1疗程(14天/疗程)。观察对比治疗前后两组病例的中医证候、生活质量等相关指标,进行统计学分析。结果:1.两组患者的治疗后有效率:治疗组有效率86.67%,对照组有效率73.33%,治疗组疗效优于对照组(P0.05)。2.脾肾阳虚症状积分:两组病例治疗后的中医证候积分均较前明显下降(P0.01),但两者疗效比较:治疗组疗效都明显优于对照组(P0.05)。3.功能状态(KPS)评分:治疗后两组病例KPS评分较治疗前均有升高,差异具有统计学意义(P0.05);治疗后两组病例的KPS评分组间比较,差异不显著(P0.05)。4.生活质量(QOL)评分:治疗后两组病例QOL评分都较前均明显提高(P0.01);治疗后两组病例QOL评分组间比较差异极显著(P0.01),说明治疗后QOL评分提高方面治疗组明显优于对照组。5.疗效指标:两组患者的肿瘤标记物CA125、血常规指标均无明显下降或升高,差异无统计学意义,其P值均0.05。两组患者免疫指标T细胞亚群治疗后较治疗前均有显著提升(P0.05),治疗组明显优于对照组(P0.05)。6.安全指标:各组安全指标无异常波动(P0.05);未发生不良反应。结论:扶阳益气方对卵巢癌患者化疗后脾肾阳虚证有明显的疗效,并能有效改善患者的中医临床症状,提高其生活质量,该治疗安全有效,无明显毒副反应。
[Abstract]:Objective: to observe and evaluate the clinical effect of Fuyang Yiqi prescription in treating the syndrome of deficiency of spleen and kidney yang after chemotherapy of ovarian cancer.To explore the treatment methods and ideas of spleen and kidney yang deficiency syndrome after ovarian cancer chemotherapy, to provide guarantee for the smooth progress and completion of chemotherapy in ovarian cancer patients, in order to improve the quality of life and prolong the survival time of ovarian cancer patients.Methods: the patients who met the criteria were randomly divided into two groups: treatment group (n = 30) and control group (n = 30).The treatment group was treated with Fuyang Yiqi prescription Shenqi Fuzheng injection and the control group was only treated with Shenqi Fuzheng injection. Both groups were treated for 14 days / course of treatment.Observe and compare the two groups of patients before and after treatment of TCM syndrome, quality of life and other related indicators, statistical analysis.The result is 1: 1.The effective rate after treatment was 86.67 in the treatment group and 73.33 in the control group. The curative effect of the treatment group was better than that of the control group (P 0.05).The symptom integral of deficiency of spleen and kidney yang: after treatment, the TCM syndrome scores of the two groups were significantly lower than that of the former, but the curative effect of the treatment group was significantly better than that of the control group (P 0.05N. 3).After treatment, the KPS score of the two groups was higher than that before treatment, and the difference was statistically significant (P 0.05), but there was no significant difference in the KPS score between the two groups after treatment.Quality of life (QOL) score: after treatment, the QOL scores of the two groups were significantly higher than those of the former, and the difference of the QOL scores between the two groups was very significant (P 0.01), indicating that the improvement of the QOL score in the treatment group was significantly better than that in the control group (P 0.05).Curative effect index: the tumor marker CA125 and the blood routine index of the two groups were not significantly decreased or increased, and the difference was not statistically significant (P < 0.05).The immunological index of T cell subsets in both groups was significantly higher than that before treatment, and the treatment group was significantly better than the control group.Safety index: there was no abnormal fluctuation of safety index in each group (P 0.05) and no adverse reaction.Conclusion: Fuyang Yiqi prescription has obvious curative effect on the syndrome of deficiency of spleen and kidney yang after chemotherapy in patients with ovarian cancer, and can effectively improve the clinical symptoms of Chinese medicine and improve the quality of life of the patients. The treatment is safe and effective, and has no obvious side effects.
【学位授予单位】：云南中医学院
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R273

【参考文献】

中国期刊全文数据库 前10条

1 莫建澍;王彬彬;沈敏鹤;;吴良村论治卵巢癌临床经验探析[J];浙江中医药大学学报;2016年09期

2 武静莲;徐强;谢亲建;白泽明;韩金萍;李晓芳;方晓霞;;党参抗肿瘤药理作用研究[J];西部中医药;2016年08期

3 张丽;何若苹;蒋丽;;何若苹治疗卵巢癌经验浅析[J];浙江中医药大学学报;2016年07期

4 王冬梅;杨格娟;王莹;美克热阿依;庞瑞;;晚期卵巢癌患者中医体质类型与中医证型的相关性研究[J];现代中西医结合杂志;2016年17期

5 张力文;李柳宁;何春霞;刘伟胜;;刘伟胜教授治疗卵巢癌的临床经验[J];成都中医药大学学报;2016年02期

6 徐硕;姜文清;邝咏梅;吴学军;马捷;金鹏飞;;茯苓的化学成分及生物活性研究进展[J];西北药学杂志;2016年03期

7 徐先容;;黄芪桂枝五物汤加减对卵巢癌TP方案化疗引起神经毒性的防治效果[J];陕西中医;2016年04期

8 樊长征;洪巧瑜;;党参对人体各系统作用的现代药理研究进展[J];中国医药导报;2016年10期

9 王守忠;高志安;;真武汤联合紫衫醇+卡铂(TC)方案治疗卵巢癌术后患者的近期临床效果[J];中国生化药物杂志;2015年12期

10 蒲玉华;;腹腔镜手术在复发性卵巢癌中的应用价值[J];实用妇产科杂志;2015年09期

中国重要会议论文全文数据库 前1条

1 刘建文;;砂仁的药理研究[A];新世纪全国中药研究暨中药房管理学术研讨会论文汇编[C];2001年

中国硕士学位论文全文数据库 前1条

1 张冬青;黄芪总黄酮及其活性成分对肿瘤细胞的抑制作用与机理研究[D];中国人民解放军军医进修学院;2010年

，

本文编号：1769866